Clinical Trial Update: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of eftilagimod alpha (IMP321) with pembrolizumab in patients with previously untreated unresectable or metastatic non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• eftilagimod alpha (eftilagimod alpha)

Snippet

Sponsor: Immutep S.A.S. | Conditions: NSCLC, HNSCC | Phase 2 | Status: COMPLETED | Results posted: 2024-12-18